Loading
Cells that survive treatment often change how they make energy, relying on burning fat rather than sugar. Blocking that switch might finish them off.
Drug-tolerant persisters and residual disease cells show increased oxidative phosphorylation and fatty acid oxidation dependence in melanoma, lung and leukaemia models. OXPHOS and fatty acid oxidation inhibitors have entered early clinical testing, with tolerability as the main issue. The proposal is intermittent, response-triggered administration at the point of maximal response rather than continuous use in bulk disease.
Shares Dormant cells and minimal residual disease, Drug resistance (primary and acquired), Acquired resistance to every therapy, Minimal / molecular residual disease (MRD).
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Minimal / molecular residual disease (MRD).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Melanoma.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy, Melanoma.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.
Shares Drug resistance (primary and acquired), Acquired resistance to every therapy.